Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Buy
57
AVXL Quote, Financials, Valuation and Earnings
Last price:
$8.92
Seasonality move
:
7.13%
Day range:
$8.05 - $8.62
52-week range:
$3.63 - $14.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.37x
Volume:
889.5K
Avg. volume:
888.6K
1-year change:
128.38%
Market cap:
$735.1M
Revenue:
--
EPS (TTM):
-$0.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
-- | -$0.15 | -- | -3.57% | $34.33 |
|
BNGO
Bionano Genomics
|
$6.3M | -$1.11 | -11.23% | -97.97% | $7.33 |
|
EDIT
Editas Medicine
|
$706.1K | -$0.59 | 251.82% | -54.6% | $3.38 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
$8.61 | $34.33 | $735.1M | -- | $0.00 | 0% | -- |
|
BNGO
Bionano Genomics
|
$3.54 | $7.33 | $11.9M | -- | $0.00 | 0% | 0.15x |
|
EDIT
Editas Medicine
|
$2.16 | $3.38 | $180.8M | -- | $0.00 | 0% | 4.98x |
|
NBY
NovaBay Pharmaceuticals
|
$0.60 | $0.85 | $3.5M | -- | $0.00 | 0% | 0.16x |
|
OGEN
Oragenics
|
$4.35 | $1.00 | $3.1M | -- | $0.00 | 0% | 1.39x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
-- | -0.401 | -- | -- |
|
BNGO
Bionano Genomics
|
21.3% | -0.801 | 150.7% | 0.82x |
|
EDIT
Editas Medicine
|
-- | 0.807 | -- | 3.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
-- | -$12.4M | -- | -- | -- | -$5.9M |
|
BNGO
Bionano Genomics
|
$2.9M | -$8.5M | -112.51% | -141.6% | -46.62% | -$2.8M |
|
EDIT
Editas Medicine
|
-- | -$35.3M | -139.77% | -139.77% | -1585.92% | -$47.9M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Anavex Life Sciences vs. Competitors
-
Which has Higher Returns AVXL or BNGO?
Bionano Genomics has a net margin of -- compared to Anavex Life Sciences's net margin of -48.04%. Anavex Life Sciences's return on equity of -- beat Bionano Genomics's return on equity of -141.6%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.13 -- BNGOBionano Genomics45.5% -$1.15 $61.2M -
What do Analysts Say About AVXL or BNGO?
Anavex Life Sciences has a consensus price target of $34.33, signalling upside risk potential of 298.76%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 107.16%. Given that Anavex Life Sciences has higher upside potential than Bionano Genomics, analysts believe Anavex Life Sciences is more attractive than Bionano Genomics.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 BNGOBionano Genomics0 2 0 -
Is AVXL or BNGO More Risky?
Anavex Life Sciences has a beta of 0.677, which suggesting that the stock is 32.257% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.277, suggesting its more volatile than the S&P 500 by 127.739%.
-
Which is a Better Dividend Stock AVXL or BNGO?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or BNGO?
Anavex Life Sciences quarterly revenues are --, which are smaller than Bionano Genomics quarterly revenues of $6.5M. Anavex Life Sciences's net income of -$11.2M is lower than Bionano Genomics's net income of -$3.1M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 0.15x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.2M BNGOBionano Genomics0.15x -- $6.5M -$3.1M
-
Which has Higher Returns AVXL or EDIT?
Editas Medicine has a net margin of -- compared to Anavex Life Sciences's net margin of -1633.49%. Anavex Life Sciences's return on equity of -- beat Editas Medicine's return on equity of -139.77%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.13 -- EDITEditas Medicine-- -$0.92 $62.4M -
What do Analysts Say About AVXL or EDIT?
Anavex Life Sciences has a consensus price target of $34.33, signalling upside risk potential of 298.76%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 56.25%. Given that Anavex Life Sciences has higher upside potential than Editas Medicine, analysts believe Anavex Life Sciences is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 EDITEditas Medicine4 8 0 -
Is AVXL or EDIT More Risky?
Anavex Life Sciences has a beta of 0.677, which suggesting that the stock is 32.257% less volatile than S&P 500. In comparison Editas Medicine has a beta of 2.100, suggesting its more volatile than the S&P 500 by 109.954%.
-
Which is a Better Dividend Stock AVXL or EDIT?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or EDIT?
Anavex Life Sciences quarterly revenues are --, which are smaller than Editas Medicine quarterly revenues of $4.7M. Anavex Life Sciences's net income of -$11.2M is higher than Editas Medicine's net income of -$76.1M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 4.98x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.2M EDITEditas Medicine4.98x -- $4.7M -$76.1M
-
Which has Higher Returns AVXL or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Anavex Life Sciences's net margin of -49.65%. Anavex Life Sciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.13 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About AVXL or NBY?
Anavex Life Sciences has a consensus price target of $34.33, signalling upside risk potential of 298.76%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Anavex Life Sciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Anavex Life Sciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is AVXL or NBY More Risky?
Anavex Life Sciences has a beta of 0.677, which suggesting that the stock is 32.257% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock AVXL or NBY?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or NBY?
Anavex Life Sciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Anavex Life Sciences's net income of -$11.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.2M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns AVXL or OGEN?
Oragenics has a net margin of -- compared to Anavex Life Sciences's net margin of --. Anavex Life Sciences's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.13 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About AVXL or OGEN?
Anavex Life Sciences has a consensus price target of $34.33, signalling upside risk potential of 298.76%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 589.72%. Given that Oragenics has higher upside potential than Anavex Life Sciences, analysts believe Oragenics is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 OGENOragenics0 1 0 -
Is AVXL or OGEN More Risky?
Anavex Life Sciences has a beta of 0.677, which suggesting that the stock is 32.257% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock AVXL or OGEN?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or OGEN?
Anavex Life Sciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Anavex Life Sciences's net income of -$11.2M is lower than Oragenics's net income of -$2.2M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 1.39x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.2M OGENOragenics1.39x -- -- -$2.2M
-
Which has Higher Returns AVXL or TOVX?
Theriva Biologics has a net margin of -- compared to Anavex Life Sciences's net margin of --. Anavex Life Sciences's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.13 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About AVXL or TOVX?
Anavex Life Sciences has a consensus price target of $34.33, signalling upside risk potential of 298.76%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1398.61%. Given that Theriva Biologics has higher upside potential than Anavex Life Sciences, analysts believe Theriva Biologics is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 TOVXTheriva Biologics1 1 0 -
Is AVXL or TOVX More Risky?
Anavex Life Sciences has a beta of 0.677, which suggesting that the stock is 32.257% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock AVXL or TOVX?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or TOVX?
Anavex Life Sciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Anavex Life Sciences's net income of -$11.2M is lower than Theriva Biologics's net income of -$4.3M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.2M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.
Buy
75
ARQQ alert for Jun 17
Arqit Quantum [ARQQ] is up 6.36% over the past day.
Buy
59
SYM alert for Jun 17
Symbotic [SYM] is down 3.91% over the past day.
